Work

Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.5_suppl.364

Authors: Toni K. Choueiri, Sumanta Kumar Pal, David F. McDermott, David A. Ramies, Stephanie Morrissey, Yihua Lee, Dale Miles, Jaymes S. Holland, Janice P. Dutcher

Institutions: Brigham and Women's Hospital, City Of Hope National Medical Center, Beth Israel Deaconess Medical Center, St. Luke's-Roosevelt Hospital Center, Harvard University, Exelixis (United States), Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4240871410

Cites:

Cited by: 15

Related to: 10